Biomarker-guided therapies in heart failure: A forum for unified strategies

Journal of Cardiac Failure

Volumn 19, Issue 8, 2013, Pages 592-599

  Fiuzat, Mona ^a   O'Connor, Christopher M ^a   Gueyffier, Francois ^b   Mascette, Alice M ^c   Geller, Nancy L ^c   Mebazaa, Alexandre ^d   Voors, Adriaan A ^e   Adams, Kirkwood F ^f   Piña, Ileana L ^g   Neyses, Ludwig ^h   Muntendam, Pieter ⁱ   Felker, G Michael ^a   Pitt, Bertram ^j   Zannad, Faiez ^k   Bristow, Michael R ^l,m  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d HÔPITAL LARIBOISIÈRE   (France)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ BG Medicine   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITÉ DE LORRAINE   (France)

^l UNIVERSITY OF COLORADO   (United States)

^m ARCA Biopharma   (United States)

more..

Author keywords

biologic markers; cardiovascular diseases; clinical trials; Pharmacogenetics

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; MALONALDEHYDE; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

EUROPEAN UNION; GENOMICS; GOVERNMENT; HEART FAILURE; HUMAN; METABOLOMICS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; UNITED STATES;

BIOLOGIC MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; PHARMACOGENETICS;

BIOLOGICAL MARKERS; EUROPE; EUROPEAN UNION; HEART FAILURE; HUMANS; PARIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES;

EID: 84881148332     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.05.012     Document Type: Review

References (78)

1. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51
2. D.F. Hayes, A.D. Thor, L.G. Dressler, D. Weaver, S. Edgerton, and D. Cowan HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 2007 1496 1506
3. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N Engl J Med 353 2005 172 187
4. M.J. Higgins, J.M. Rae, D.A. Flockhart, D.F. Hayes, and V. Stearns Pharmacogenetics of tamoxifen: who should undergo Cyp2d6 genetic testing? J Natl Compr Canc Netw 7 2009 203 213
5. R.D. Kociol, J.R. Horton, G.C. Fonarow, E.M. Reyes, L.K. Shaw, and C.M. O'Connor Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: Data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) linked to Medicare claims Circ Heart Fail 4 2011 628 636
6. A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, and W.B. Borden Heart Disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 2013 e6 245
7. M. Metra, J.R. Teerlink, A.A. Voors, G.M. Felker, O. Milo-Cotter, and B. Weatherley Vasodilators in the treatment of acute heart failure: what we know, what we don't Heart Fail Rev 14 2009 299 307
8. G.M. Felker, V. Hasselblad, A.F. Hernandez, and C.M. O'Connor Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials Am Heart J 158 2009 422 430
9. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, and K. Dickstein ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur Heart J 33 2012 1787 1847
10. M. Jessup, W.T. Abraham, D.E. Casey, A.M. Feldman, G.S. Francis, and T.G. Ganiats 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977 2016
11. R. Simon Clinical trials for predictive medicine Stat Med 25 2012 3031 3040
12. R. Simon Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology Pers Med 1 2010 33 47
13. D. Sargent, B.A. Conley, C. Allegra, and L. Collette Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2005 2020 2027
14. J.P. Boissel, R. Kahoul, E. Amsallem, F. Gueyffier, M. Haugh, and F.H. Boissel Toward personalized medicine: exploring the consequences of the effect model-based approach Pers Med 8 2011 581 586
15. P.M. Ridker, N.R. Cook, I.M. Lee, D. Gordon, J.M. Gaziano, and J.E. Manson A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
16. M.R. Bristow Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology Circ Res 109 2011 1176 1194
17. P. de Groote, N. Helbecque, N. Lamblin, X. Hermant, E. Mc Fadden, and C. Foucher-Hossein Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure Pharmacogenet Genomics 15 2005 137 142
18. S.B. Liggett, J. Mialet-Perez, S. Thaneemit-Chen, S.A. Weber, S.M. Greene, and D. Hodne A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure Proc Natl Acad Sci U S A 103 2006 11288 11293
19. D.A. Mason, J.D. Moore, S.A. Green, and S.B. Liggett A gain-of-function polymorphism in a g-protein coupling domain of the human beta1-adrenergic receptor J Biol Chem 274 1999 12670 12674
20. J. Mialet Perez, D.A. Rathz, N.N. Petrashevskaya, H.S. Hahn, L.E. Wagoner, and A. Schwartz Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure Nat Med 9 2003 1300 1305
21. A.J. Sehnert, S.E. Daniels, M. Elashoff, J.A. Wingrove, C.R. Burrow, and B. Horne Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol J Am Coll Cardiol 52 2008 644 651
22. A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus MERIT-HF Study Group Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) JAMA 283 2000 1295 1302
23. D.M. McNamara, S.W. Tam, M.L. Sabolinski, P. Tobelmann, K. Janosko, and A.L. Taylor Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial J Am Coll Cardiol 48 2006 1277 1282
24. S. de Denus, M. Zakrzewski-Jakubiak, M.P. Dubé, F. Bélanger, S. Lepage, and M.H. Leblanc Effects of AGTR1 a1166c gene polymorphism in patients with heart failure treated with candesartan Ann Pharmacother 42 2008 925 932
25. L. Kurland, H. Melhus, J. Karlsson, T. Kahan, K. Malmqvist, and P. Ohman Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA) trial J Hypertens 20 2002 657 663
26. M. Cicoira, A. Rossi, S. Bonapace, L. Zanolla, A. Perrot, and D.P. Francis Effects of ace gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure Am J Med 116 2004 657 661
27. M. Fiuzat, M.L. Neely, A.Z. Starr, W.E. Kraus, G.M. Felker, and M. Donahue Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy Eur J Heart Fail 15 2013 258 266
28. L.E. Wagoner, L.L. Craft, B. Singh, D.P. Suresh, P.W. Zengel, and N. McGuire Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure Circ Res 86 2000 834 840
29. H. Wieneke, C.N. Naber, L. Piaszek, S. Sack, U.H. Frey, and G. Heusch Better identification of patients who benefit from implantable cardioverter defibrillators by genotyping the G-protein beta3 subunit (GNB3) c825t polymorphism Basic Res Cardiol 101 2006 447 451
30. P.A. Gurbel, and U.S. Tantry Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287
31. T. Ahmad, D. Voora, and R.C. Becker The pharmacogenetics of antiplatelet agents: toward personalized therapy? Nat Rev Cardiol 8 2011 560 571
32. M.R. Bristow, G.A. Murphy, H. Krause-Steinrauf, J.L. Anderson, J.F. Carlquist, and S. Thaneemit-Chen An alpha2c-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
33. D.M. McNamara Pharmacogenomics for neurohormonal intervention in heart failure Cardiol Clin 26 2008 127 135
34. D.M. McNamara Emerging role of pharmacogenomics in heart failure Curr Opin Cardiol 23 2008 261 268
35. A.J. Hautala, T. Rankinen, A.M. Kiviniemi, T.H. Makikallio, H.V. Huikuri, and C. Bouchard Heart rate recovery after maximal exercise is associated with acetylcholine receptor M2 (CHRM2) gene polymorphism Am J Physiol Heart Circ Physiol 291 2006 H459 H466
36. S.B. Liggett, S. Cresci, R.J. Kelly, F.M. Syed, S.J. Matkovich, and H.S. Hahn A Grk5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure Nat Med 14 2008 510 517
37. J.E. Rame, M.H. Drazner, W. Post, R. Peshock, J. Lima, and R.S. Cooper Corin i555(p568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload Hypertension 49 2007 857 864
38. J.L. Januzzi Jr., R. Sakhuja, M. O'Donoghue, A.L. Baggish, S. Anwaruddin, and C.U. Chae Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department Arch Intern Med 166 2006 315 320
39. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
40. P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, and J.F. Aupetit Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study J Am Coll Cardiol 49 2007 1733 1739
41. M. Pfisterer, P. Buser, H. Rickli, M. Gutmann, P. Erne, P. Rickenbacher, and A. Vuillomenet BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial JAMA 301 2009 383 392
42. H. Persson, H. Erntell, B. Eriksson, G. Johansson, K. Swedberg, and U. Dahlström Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP guided management of heart failure - SIGNAL-HF (Swedish Intervention Study - Guidelines and NT-proBNP Analysis in Heart Failure) Eur J Heart Fail 12 2010 1300 1308
43. L.W. Eurlings, P.E. van Pol, W.E. Kok, S. van Wijk, C. Lodewijks-van der Bolt, and A.H. Balk Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?) study J Am Coll Cardiol 56 2010 2090 2100
44. R. Berger, D. Moertl, S. Peter, R. Ahmadi, M. Huelsmann, and S. Yamuti N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study J Am Coll Cardiol 55 2010 645 653
45. J.G. Lainchbury, R.W. Troughton, K.M. Strangman, C.M. Frampton, A. Pilbrow, and T.G. Yandle N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial J Am Coll Cardiol 55 2009 53 60
46. J.L. Januzzi Jr., S.U. Rehman, A.A. Mohammed, A. Bhardwaj, L. Barajas, and J. Barajas Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
47. P. Karlström, U. Alehagen, K. Boman, U. Dahlström UPSTEP Study Group Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome Eur J Heart Fail 13 2011 1096 1103
48. M.R. Shah, R.M. Califf, A. Nohria, M. Bhapkar, M. Bowers, and D.M. Mancini The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure J Card Fail 17 2011 613 621
49. M. Anguita, F. Esteban, J.C. Castillo, F. Mazuelos, A. López-Granados, J.M. Arizón, and J. Suárez de Lezo [Usefulness of brain natriuretic peptide levels, compared with usual clinical control, for the treatment monitoring of patients with heart failure] Med Clin (Barc) 135 2010 435 440 Spanish
50. Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. http://dx.doi.org/10.1016/j.bbadis.2012.12.014.
51. E. Braunwald Biomarkers in heart failure N Engl J Med 358 2008 2148 2159
52. J.L. Januzzi Jr., W.F. Peacock, A.S. Maisel, C.U. Chae, R.L. Jesse, and A.L. Baggish Measurement of the interleukin family member st2 in patients with acute dyspnea: results from the pride (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study J Am Coll Cardiol 50 2007 607 613
53. R.R. van Kimmenade, J.L. Januzzi Jr., P.T. Ellinor, U.C. Sharma, J.A. Bakker, and A.F. Low Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
54. T. Kempf, S. von Haehling, T. Peter, T. Allhoff, M. Cicoira, and W. Doehner Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure J Am Coll Cardiol 50 2007 1054 1060
55. K.C. Wollert, and T. Kempf Growth differentiation factor 15 in heart failure: an update Curr Heart Fail Rep 9 2012 337 345
56. A. Maisel, C. Mueller, R. Nowak, W.F. Peacock, J.W. Landsberg, and P. Ponikowski Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial J Am Coll Cardiol 55 2010 2062 2076
57. S.R. Motiwala, and J.L. Januzzi Jr Using biomarkers to guide heart failure management: current perspectives and future directions Cardiol Rev 21 2013 127 134
58. A.S. Maisel, and R. Choudhary Biomarkers in acute heart failure - state of the art Nat Rev Cardiol 9 2012 478 490
59. T. Ahmad, M. Fiuzat, G.M. Felker, and C. O'Connor Novel biomarkers in chronic heart failure Nat Rev Cardiol 9 2012 347 359
60. A. Mebazaa, G. Vanpoucke, G. Thomas, K. Verleysen, A. Cohen-Solal, and M. Vanderheyden Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure Eur Heart J 33 2012 2317 2324
61. F. Zannad, F. Alla, B. Dousset, A. Perez, and B. Pitt Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES) Circulation 102 2000 2700 2706
62. L. Gullestad, T. Ueland, J. Kjekshus, S.H. Nymo, J. Hulthe, and P. Muntendam Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) Eur Heart J 33 2012 2290 2296
63. N. Sherwi, S. Merali, and K. Wong Personalizing biomarker strategies in heart failure with galectin-3 Future Cardiol 8 2012 885 894
64. W. Doehner Diagnostic biomarkers in cardiovascular disease: the proteomics approach Eur Heart J 33 2012 2249 2251
65. J.G. Lainchbury, R.W. Troughton, C.M. Frampton, T.G. Yandle, A. Hamid, and M.G. Nicholls NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial Eur J Heart Fail 8 2006 532 538
66. G.C. Fonarow The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure Rev Cardiovasc Med 4 Suppl 7 2003 S21 S30
67. C.M. O'Connor, N.M. Albert, A.B. Curtis, M. Gheorghiade, J.T. Heywood, and M.L. McBride Patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE HF trial) Am J Cardiol 107 2011 250 258
68. J.G. Cleland, J.J. McMurray, J. Kjekshus, J.H. Cornel, P. Dunselman, and C. Fonseca Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) J Am Coll Cardiol 54 2009 1850 1859
69. N. Lopez-Andrès, P. Rossignol, W. Iraqi, R. Fay, J. Nuée, and S. Ghio Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial Eur J Heart Fail 14 2012 74 81
70. M.A. Hlatky, P. Greenland, D.K. Arnett, C.M. Ballantyne, M.H. Criqui, and M.S. Elkind Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
71. European Commission; Research and innovation - health. Available at: http://ec.europa.eu/research/health/medical-research/index-en.html. Accessed June 8, 2012.
72. INSERM; HOMAGE - overcoming heart failure: a European challenge. Press release, February 18, 2013. Available at: http://presse-inserm.fr/en/homage- combattre-linsuffisance-cardiaque-un-enjeu-a-dimension-europeenne/6750/. Accessed February 19, 2013.
73. European Commission; Research and innovation - health. Policy issues. Available at: http://ec.europa.eu/research/health/policy-issues-personalised- medicine-en.html. Accessed June 8, 2012.
74. European Commission;. Research and innovation-Horizon 2020. Available at: http://ec.europa.eu/research/horizon2020/index-en.cfm. Accessed June 8, 2012.
75. National Heart, Lung, and Blood Institute. Strategic plan publications. Available at: http://www.nhlbi.nih.gov/about/strategicplan/publications.htm. Accessed June 8, 2012.
76. National Heart, Lung, and Blood Institute. The Joint NHLBI-PMC-ACC-AMA- GWU conference, "New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care." Available at: http://www.nhlbi.nih.gov/ meetings/workshops/joint-cardiovascular.htm. Accessed June 8, 2012.
77. National Heart, Lung, and Blood Institute. National Heart, Lung, and Blood Institute Working Group on Cardiovascular Pharmacogenomics. Available at: http://www.nhlbi.nih.gov/meetings/workshops/group-cardiovascular.htm. Accessed June 8, 2012.
78. Database of Genotypes and Phenotypes. Available at: http://www.ncbi.nlm. nih.gov/sites/entrez?db=gap. Accessed June 8, 2012.